Synthesis and in vitro-anticancer and antimicrobial evaluation of some novel quinoxalines derived from 3-phenylquinoxaline-2(1 H)-thione

Archiv der Pharmazie

Volumn 339, Issue 8, 2006, Pages 437-447

  El Hawash, Soad A M ^a   Wahab, Abeer E Abdel ^b  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b Universities and Research centers District   (Egypt)

Author keywords

2 (Hydrazinocarbonylmethylthio) 3 phenylquinoxaline; 3 Phenylquinoxaline 2(1 H) thione; Antitumor activities, Antimicrobial activities; N Arylchloroacetamides

Indexed keywords

2 (HYDRAZINOCARBONYLMETHYLTHIO) 3 PHENYLQUINOXALINE; 2 (N ARYLCARBAMOYLMETHYLSULFONYL) 3 PHENYLQUINOXALINE; 2 (N ARYLCARBAMOYLMETHYLTHIO) 3 PHENYLQUINOXALINE; 2 (N ARYLIDENEHYDRAZINOCARBONYLMETHYLTHIO) 3 PHENYLQUINOXALINE; 2 (N ARYLTHIOCARBAMOYLHYDRAZINOCARBONYLMETHYLTHIO) 3 PHENYLQUINOXALINE; 2 [(1 ARYLETHYLIDENE)HYDRAZINOCARBONYLMETHYLTHIO] 3 PHENYLQUINOXALINE; 2 [(3 ARYL 4 OXOTHIAZOLIDIN 2 YLIDENE)HYDRAZINOCARBONYLMETHYLTHIO] 3 PHENYLQUINOXALINE; 2 [(3,4 DISUBSTITUTED 2,3 DIHYDROTHIAZOL 2 YLIDENE) HYDRAZINOCARBONYL METHYLTHIO] 3 PHENYLQUINOXALINE HYDROBROMIDE; 2 [(5 ARYLAMINO 1,3,4 OXADIAZOL 2 YL)METHYLTHIO] 3 PHENYLQUINOXALINE; 2 [(5 ARYLAMINO 1,3,4 THIADIAZOL 2 YL)METHYLTHIO] 3 PHENYLQUINOXALINE; 2 ETHOXYCARBONYLMETHYLTHIO 3 PHENYLQUINOXALINE; 3 PHENYLQUINOXALINE 2(1H) THIONE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; QUINOXALINE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

AMPICILLIN; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIA; CANDIDA ALBICANS; CELL LINE, TUMOR; CELL PROLIFERATION; CLOTRIMAZOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GROWTH INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIONES;

EID: 33748260364     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200600012     Document Type: Article

References (33)

1. B. Zarranz, A. Jaso, I. Aldana, A. Monge, Bioorg. Med. Chem. 2004, 12, 3711-3721.
2. H. Gao, E. F. Yamasaki, K. K. Chan, L. L. Shen, R. M. Snapka, Mol. Pharmacol. 2003, 63, 1382-1388.
3. D. S. Lawrence, J. E. Copper, C. D. Smith, J. Med. Chem. 2001, 44, 594-601.
4. G. Vitale, P. Corona, M. Loriga, G. Paglietti, Farmaco 1998, 53, 150-159.
5. Z. Ding, R. E. Parchment, P. M. LoRusso, J. Y. Zhou, et al., Clin. Cancer Res. 2001, 7, 3336-3342.
6. J. R. Rigas, W. P. Tong, M. G. Kris, J. P. Orazem, et al., Cancer Res. 1992, 52, 6619-6623.
7. G. Campiani, F. Aiello, M. Fabbrini, E. Morelli, et al., J. Med. Chem. 2001, 44, 305-315.
8. J. P. Kleim, R. Bender, R. Kirsch, C. Meichsner, et al., Antimicrob. Agents Chemother. 1995, 39, 2253-2257.
9. K. Mori, Y. Yasutomi, S. Sawada, F. Villinger, et al., J. Virol. 2000, 74, 5747-5753.
10. Y. B. Kim, Y. H. Kim, J. Y. Park, S. K. Kim, Bioorg. Med. Chem. Lett. 2004, 14, 541-544.
11. A. Carta, M. Loriga, G. Paglietti, A. Mattana, et al., Eur. J. Med. Chem. 2004, 39, 195-203.
12. A. Carta, M. Lorgia, S. Zanetti, L. A. Sechi, Farmaco 2003, 58, 1251-1255.
13. J. Harmenberg, A. Akesson-Johansson, A. Graslund, T. Malmfors, et al., Antiviral. Res. 1991, 15, 193-204.
14. N. S. Habib, S. A. El-Hawash, Pharmazie 1997, 52, 594-598.
15. S. A. El-Hawash, N. S. Habib, N. H. Fanaki, Pharmazie 1999, 54, 808-813.
16. N. S. Habib, S. A. El-Hawash, Boll. Chim. Farmaco. 2005, 144(5), 1.
17. A. Varvaresou, A. Tsantili-KaKoulidou, T. Siatra-Papastaikoudi, E. Tiligada, Arzneim. Forsc. 2000, 50, 48-54.
18. F. P. Invidiata, D. Simoni, F. Scintu, N. Pinna, Farmaco 1996, 52, 659-664.
19. H. N. Dogan, A. Duran, S. Rollas, G. Sener, et al., Bioorg. Med. Chem. 2002, 10, 2893-2898.
20. K. A. Jassen, N. M. English, J. Yu Wang, S. Maliartchouk, et al., Mol. Cancer Ther. 2005, 4, 761-771.
21. H. Z. Zhang, S. Kasibhatla, J. Kuemmerle, W. Kemnitzer, et al., J. Med. Chem. 2005, 48, 5215-5223.
22. A. A. El-Eman, O. A. Al-Deeb, M. AL-Omar, J. Lehemann, Bioorg. Med. Chem. 2004, 12, 5107-5113.
23. S. G. Kucukguzel, E. E. Oruc, S. Rollas, F. Sahin, A. Ozbek, Eur. J. Med. Chem. 2002, 37, 197-206.
24. G. Turan-Zitouni, Z. A. Kaplancikli, M. T. Yildiz, P. Chevallet, D. Kaya, Eur. J. Med. Chem. 2005, 40, 607-613.
25. C. G. Bonde, N. J. Gaikwad, Bioorg Med. Chem. 2004, 12, 2151-2161.
26. R. N. Misra, H. Y. Xiao, D. K. Williams, K. S. Kim, et al., Bioorg. Med. Chem. Lett. 2004, 14, 2973-2977.
27. G. Westphal, H. Wasicki, U. Zielinski, F. G. Weber, et al., Pharmazie 1977, 32, 687-689.
28. P. Jimonet, F. Audiau, M. Barreau, J.-C. Blanchard, et al., J. Med. Chem. 1999, 42, 2828-2843.
29. M. R. Grever, S. A. Schepartz, B. A. Chabner, Semin. Oncol. 1992, 19, 622-638.
30. M. R. Boyed, K. D. Paull, Drug Dev. Res. 1995, 34, 91-109.
31. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, et al., J. Natl. Caner Inst. 1991, 83, 757-766.
32. S. R. Jain, A. Kar, Planta Med. 1971, 20, 118-123.
33. th ed. 1989, 2, 161-181.